BRCA1 and hereditary cancer: PARPI therapy (alone or in combination with ARSI) is the preferred first-line targeted option for patients with pathogenic HRR alterations detected in either tissue or ctDNA, with genetic counseling indicated for germline BRCA1/2 carriers due to the associated hereditary cancer risk.